Patient resources- sarcoma cutaneous histiocytoma cancer treatment

Sarcoma is a rare cancer in adults (1% of all adult cancers), but rather prevalent in children (about 20% of all childhood cancers). It is made up of many “subtypes” because it can arise from a variety of tissue structures cutaneous histiocytoma (nerves, muscles, joints, bone, fat, blood vessels – collectively referred to as the body’s “connective tissues”). Because these tissues are found everywhere on the body, sarcomas can arise anywhere. Thus, within each site of the more “common” cancers there is the occasional surprise sarcoma diagnosis (e.G., breast sarcoma, stomach sarcoma, lung sarcoma, ovarian sarcoma, etc.). The most frequent location are the limbs since this is cutaneous histiocytoma where the majority of the body’s connective tissue resides. They are commonly hidden deep in the body, so sarcoma is often diagnosed when it has already become cutaneous histiocytoma too large to expect a hope of being cured. Although a lot of the lumps and bumps we get cutaneous histiocytoma are benign, people should have them looked at by a doctor at cutaneous histiocytoma an early stage in case it is sarcoma.

Sarcoma is sometimes curable by surgery (about 20% of the time), or by surgery with chemotherapy and/or radiation (another 30%), but about half the time they are totally resistant to cutaneous histiocytoma all of these approaches—thus the extreme need for new therapeutic approaches. At any one time, about 50,000 patients and their families are struggling with sarcoma. Approximately 15,000 new cases are diagnosed each year nearly 6,000 people die each year from sarcoma.

Sarcomas can invade surrounding tissue and can metastasize (spread) to other organs of the body, forming secondary tumors. The cells of secondary tumors are similar to those of cutaneous histiocytoma the primary (original) cancer. Secondary tumors are referred to as “metastatic sarcoma” because they are part of the same cancer and are cutaneous histiocytoma not a new disease. Subtypes

Studies suggest that workers who are exposed to phenoxyacetic acid cutaneous histiocytoma in herbicides and chlorophenols in wood preservatives may have an cutaneous histiocytoma increased risk of developing sarcomas. An unusual percentage of patients with a rare blood vessel cutaneous histiocytoma tumor, angiosarcoma of the liver, for example, have been exposed to vinyl chloride in their work. This substance is used in the manufacture of certain plastics.

In the early 1900s, when scientists were just discovering the potential uses of radiation cutaneous histiocytoma to treat disease, little was known about safe dosage levels and precise methods cutaneous histiocytoma of delivery. At that time, radiation was used to treat a variety of noncancerous medical cutaneous histiocytoma problems, including enlargement of the tonsils, adenoids, and thymus gland. Later, researchers found that high doses of radiation caused sarcomas in cutaneous histiocytoma some patients. Because of this risk, radiation treatment for cancer is now planned to ensure that cutaneous histiocytoma the maximum dosage of radiation is delivered to diseased tissue cutaneous histiocytoma while surrounding healthy tissue is protected as much as possible.

Studies have focused on genetic alterations that may lead to cutaneous histiocytoma the development of sarcomas. Scientists have also found a small number of families in cutaneous histiocytoma which more than one member in the same generation has cutaneous histiocytoma developed sarcoma. There have also been reports of a few families in cutaneous histiocytoma which relatives of children with sarcoma have developed other forms cutaneous histiocytoma of cancer at an unusually high rate. Sarcomas in these family clusters, which represent a very small fraction of all cases, may be related to a rare inherited genetic alteration. However, in the vast majority of cases, sarcoma is a completely random event in a family’s cancer history.

Certain inherited diseases are associated with an increased risk of cutaneous histiocytoma developing soft tissue sarcomas. For example, people with li-fraumeni syndrome (associated with alterations in the p53 gene) or von recklinghausen’s disease (also called neurofibromatosis, and associated with alterations in the NF1 gene) are at an increased risk of developing soft tissue sarcomas. How is sarcoma diagnosed?

Surgery is the most common treatment for sarcomas. If possible, the doctor may remove the cancer and a safe margin cutaneous histiocytoma of the healthy tissue around it. Depending on the size and location of the sarcoma, it may occasionally be necessary to remove all or part cutaneous histiocytoma of an arm or leg (amputation). However, the need for amputation rarely arises; no more than 10 percent to 15 percent of individuals cutaneous histiocytoma with sarcoma undergo amputation. In most cases, limb-sparing surgery is an option to avoid amputating the arm cutaneous histiocytoma or leg. In limb-sparing surgery, as much of the tumor is removed as possible, and radiation therapy and/or chemotherapy are given either before the surgery to shrink cutaneous histiocytoma the tumor or after surgery to kill the remaining cancer cutaneous histiocytoma cells.

Chemotherapy (treatment with anticancer drugs) may be used with radiation therapy either before or after cutaneous histiocytoma surgery to try to shrink the tumor or kill any cutaneous histiocytoma remaining cancer cells. If the cancer has spread to other areas of the cutaneous histiocytoma body, chemotherapy may be used to shrink tumors and reduce the cutaneous histiocytoma pain and discomfort they cause, but is unlikely to eradicate the disease. The use of chemotherapy to prevent the spread of sarcomas cutaneous histiocytoma has not been proven to be effective. Patients with sarcomas usually receive chemotherapy intravenously (injected into a blood vessel).